- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04971330
Access Anti-HCV Assay European Union (EU) Clinical Trial Protocol (HCV-EU-10-18)
Evaluation of the Beckman Coulter Access Anti-HCV Assay as an Aid in the Diagnosis of HCV Infection: EU Clinical Trial Protocol
Studienübersicht
Detaillierte Beschreibung
The study involved a multicenter, prospective and retrospective collection of samples, and testing of samples with the investigational Access anti-HCV assay. Subject sample enrollment was targeted to be approximately 8,000 specimens including approximately 6,000 blood donors and 1,500 hospitalized individuals for the specificity populations and 500 confirmed HCV Ab positive patients for the sensitivity population, required by European Union's Common Technical Specification for clinical validation of in vitro diagnostic medical devices and marketing needs to align with competitor submissions. Retrospective collection included HCV Ab positive genotyped samples from existing vendor collections meeting all inclusion/exclusion criteria.
All samples collected were anonymized, leftover, remnant samples and therefore member state or Institutional Review Board/Independent Ethics Committee approval was not required. Diagnostic sensitivity and specificity were evaluated for sample antibody status determined by a CE-marked anti-HCV assay (Abbott ARCHITECT anti-HCV assay for hospitalized patient and positive samples or Abbott PRISM HCV assay for blood donor samples) and Immunoblot testing with FUJIREBIO INNO-LIA HCV Score, if necessary. HCV RNA Polymerase Chain Reaction (PCR) or genotyping was requested or was available on all Immunoblot positive samples for further characterization, but these results were not used to determine final antibody status.
A portion of hospitalized patient samples (target 700/1500) and the majority of positive HCV Ab samples were collected and stored frozen prior to testing. A targeted portion of 800 hospitalized patient samples, 30 known positive samples and all blood donor samples were collected and tested fresh. Fresh blood donor and fresh hospitalized patient samples were used to determine false Initial Reactive Rate (IRR).
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
-
Bois-Guillaume, Frankreich, 76232
- Etablissement Français du Sang (EFS) Hauts-de-France - Normandie
-
Ivry-sur-Seine, Frankreich, 94208
- Eurofins Biomnis
-
Saint-Ouen-l'Aumône, Frankreich, 95310
- Cerba Xpert
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
The test population includes :
- 513 Known HCV Ab Positive Patients
- 1533 Hospitalized patients
- 5855 Unselected Blood donors
Beschreibung
Inclusion Criteria:
Anonymized or pseudo-anonymised leftover ethylenediaminetetraacetic acid (EDTA) plasma/serum samples from
- Males or females
- Aged ≥18 years of age
Belonging to one of the following enrollment groups
- Unselected blood donor
- Hospitalized patient from GI, hepatology, Internal Medicine or Infectious Disease services
- Known HCV Ab positive (by Immunoblot) at different stages of disease
- with at least 1.5 mL leftover sample (without genotype or PCR on same draw) OR
- at least 0.8 mL leftover sample (with genotype or HCV PCR on same draw)
Exclusion Criteria:
- Samples from subjects already included in the study
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
---|---|
Known HCV Ab Positive Patients
leftover samples be tested with both reference anti-HCV assay and Access anti-HCV assay according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity.
Reference assay will be Abbott Architect anti-HCV assay for positive samples.
|
All samples were tested with both reference anti-HCV assay and Access anti-HCV assay according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity. Reference assay was Abbott Architect anti-HCV assay. For blood donors, Abbott PRISM HCV was used as reference. For the specificity cohorts (blood donor and hospitalized patient samples), all HCV Ab positive results will have supplemental confirmation testing with HCV Immunoblot for final HCV Ab status |
Hospitalized Patients
leftover samples be tested with both reference anti-HCV assay and Access anti-HCV assay according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity. Reference assay will be Abbott Architect anti-HCV assay for hospitalized patient. For the specificity cohorts (blood donor and hospitalized patient samples), all HCV Ab positive results will have supplemental confirmation testing with HCV Immunoblot for final HCV Ab status |
All samples were tested with both reference anti-HCV assay and Access anti-HCV assay according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity. Reference assay was Abbott Architect anti-HCV assay. For blood donors, Abbott PRISM HCV was used as reference. For the specificity cohorts (blood donor and hospitalized patient samples), all HCV Ab positive results will have supplemental confirmation testing with HCV Immunoblot for final HCV Ab status |
Unselected Blood Donors
Leftover samples be tested with both reference anti-HCV assay and Access anti-HCV assay according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity. les. For blood donors, Abbott PRISM HCV will be used as reference. For the specificity cohorts (blood donor and hospitalized patient samples), all HCV Ab positive results will have supplemental confirmation testing with HCV Immunoblot for final HCV Ab status. |
All samples were tested with both reference anti-HCV assay and Access anti-HCV assay according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity. Reference assay was Abbott Architect anti-HCV assay. For blood donors, Abbott PRISM HCV was used as reference. For the specificity cohorts (blood donor and hospitalized patient samples), all HCV Ab positive results will have supplemental confirmation testing with HCV Immunoblot for final HCV Ab status |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
sensitivity and specificity
Zeitfenster: Baseline
|
sensitivity and specificity relative to the final patient HCV Ab status determined from reference HCV Ab assay and/or supplemental confirmation testing (HCV Ab result by immunoblot).
|
Baseline
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
- DC-TR18-0406
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur HCV
-
Ascletis Pharmaceuticals Co., Ltd.Abgeschlossen
-
Ain Shams UniversityAbgeschlossen
-
PfizerAbgeschlossen
-
Bristol-Myers SquibbAbgeschlossenHCV (Genotyp 1)Vereinigte Staaten, Puerto Rico
-
Valme University HospitalBoehringer IngelheimUnbekannt
-
Johns Hopkins UniversityNational Institute of Allergy and Infectious Diseases (NIAID)Rekrutierung
-
Tibotec Pharmaceuticals, IrelandAbgeschlossen
-
Kirby InstituteAustralasian Society for HIV Viral Hepatitis and Sexual Health Medicine (ASHM) und andere MitarbeiterRekrutierung
-
Radboud University Medical CenterZurückgezogenHCVNiederlande, Deutschland
-
National Institutes of Health Clinical Center (CC)Bristol-Myers Squibb; National Institute of Allergy and Infectious Diseases...Abgeschlossen
Klinische Studien zur Access HCV
-
NYU Langone HealthJacobi Medical CenterAktiv, nicht rekrutierendHIV-InfektionenVereinigte Staaten
-
Hugo W. Moser Research Institute at Kennedy Krieger...AbgeschlossenRückenmarksverletzungVereinigte Staaten
-
Old Dominion UniversityAbgeschlossen
-
University of SaskatchewanUniversity of Alberta; Saskatchewan Health Research Foundation; Heart and Stroke... und andere MitarbeiterSuspendiert
-
ANRS, Emerging Infectious DiseasesInstitut National de la Santé Et de la Recherche Médicale, France; Fondation... und andere MitarbeiterUnbekannt
-
University of AarhusCentral Denmark Region; TrygFonden, DenmarkAbgeschlossen
-
Circa Scientific, Inc.Rekrutierung
-
University of La LagunaRekrutierung
-
ANRS, Emerging Infectious DiseasesEPISTEMAbgeschlossen
-
Phraxis, Inc.AbgeschlossenFehlfunktion des DialysezugangsVereinigte Staaten